Downstream Process Development and OEM

Healthgen Biotech, specializing in molecular pharmaceutical research and development, is focusing on developing and manufacturing a series of animal-free and safe products by using the State-of-the-Art platform called Oryz^HiExp, having a high capacity to express proteins or small peptides in the rice grain. Using the Oryz^HiExp platform, Healthgen Biotech can provide customized protein or peptides expression and purification services. The process route and infrastructure of large-scale protein purification have been established and can implement the industrial expression and production requirements.

Healthgen Biotech has a strong technical force, advanced and complete protein expression and purification technology research, and large-scale production facilities can provide high capacity and significant advantages alternative development and manufacturing approaches.

• Recombinant Protein Expression

Provide expression service of proteins of 100-1000 amino acid molecular mass and polypeptides of fewer than 100 amino acids for customers.

• Purification Process Development

Establish and optimize and cost-effective extraction and purification process protocol

• Detection Methodology Service

Developing analytic methodology method and methodology validation

Advantages Provided by Healthgen Biotech

• High expression level. The patented promotor enables the expression level to be 10~1000 times higher than other expression systems.
• Cost-effective. Rice endosperm platform is cost-effective for early-stage companies. No enormous investment of bioreactor tanks in the enlarged stage.
• Rapid scale-up production. The rice is scaled up by farming, and purified recombinant proteins or peptides can reach kilograms level with 2 years.
• High bioactivity. The recombinant proteins or peptides are expressed in the rice endosperm and stored in the rice protein body which can keep the protein stability and bioactivity to the maximum extent.
• Chemical defined. No human-derived or animal-derived components are involved in the processing, can elimination or reduction of the potential risk of viral and other unknown factors in blood-derived products.
• Solid quality system. The Healthgen Biotech facility is designed to be cGMP compliant. The quality control system has been certified by ISO 9001: 2015 and ensures standardized processes as well as qualified products. The rice-derived recombinant human serum albumin has been approved for clinical trials as a primary new drug.
• One package service. Healthgen Biotech provides a series services from recombinant protein expression and downstream process development, includes production process development, optimization, and scale-up.